Drugs / Ginsenoside Compound K
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03755258 | Mar 2017 → Jul 2019 | rheumatoid arthritis | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginsenoside Compound K | “Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis” NCT03755258 ↗ |
| Known as | GCK | “Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis” NCT03755258 ↗ |
| Route | Oral | “GCK 100 mg + Placebo 200 mg, oral, 12 weeks” NCT03755258 ↗ |